G2B BioSolutions ApSAktiv

CVR 42437069

Økonomiske nøgletal

44.817 kr.-89,7%
Bruttofortjeneste 2025
-1 mio.-500 t.0500 t.20212022202320242025

Nøgletal

2025
Balancens sammensætning
OmsætningsaktiverAnlægsaktiverGæld og hensatte forpligtelserEgenkapital
01 mio.2 mio.20212022202320242025

Selskabsskat

indkomstår 2022

Virksomheden er sambeskattet. Skatten opgøres samlet hos administrationsselskabet Dayanand Jadhav Holding ApS.

2022Skattepligtig indkomst -206.994 kr.0 kr.
2021Skattepligtig indkomst -25.139 kr.0 kr.
Selskabsskat →

Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk

Regnskabstal2021–2025
20212022202320242025
Balance — aktiver
Likvide beholdninger7.28918.5090257.42588.073
Omsætningsaktiver i alt14.29967.50450.191289.155291.534
Anlægsaktiver i alt——40.000302.745343.235
Aktiver i alt14.29967.50490.191591.900634.769
Balance — passiver
Kortfristede gældsforpligtelser2.938274.6951.311.1671.136.5191.131.524
Langfristede gældsforpligtelser——500.000805.617716.617
Gældsforpligtelser i alt2.938274.6951.811.1671.942.1361.848.141
Selskabskapital40.00040.00040.00040.00040.000
Overført resultat-28.639-247.191-1.760.976-1.390.236-1.253.372
Årets resultat-28.639-218.552-1.513.784370.740136.864
Egenkapital i alt11.361-207.191-1.720.976-1.350.236-1.213.372
Resultatopgørelse
Bruttofortjeneste-28.552-171.184-739.652435.67444.817
Resultat af primær drift-28.552-212.558-1.501.410381.2638.526
EBITDA————44.817
Resultat før skat—-217.352-1.513.784370.740-30.477
Årets resultat-28.639-218.552-1.513.784370.740136.864
Personaleomkostninger041.374761.75854.4110
Af- og nedskrivninger————36.291
Andre nøgletal
Ansatte11210

En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.

Om virksomheden

Årsrapport 2025

Business reviewThe company's purpose is to conduct business with trade, service, production and thus, at the management's discretion, related business.

Financial review The company's income statement for the year ended 31. december 2025 shows a profit of DKK 136.864, and the balance sheet at 31 December 2025 shows negative equity of DKK 1.213.372.Uncertainty about the continued operation (going concern)The company has lost its entire share capital, which is in line with management’s expectations. It is expected that the share capital will be re-established through operations once the development project has been completed. The company is financially supported by the company’s ultimate owner, who has issued a letter of support valid until the date of approval of the annual report for the financial year ended 31 December 2026. On this basis, management considers that the annual report may be prepared on a going concern basis. Reference is made to Note 1 "Uncertainty related to going concern".

Uddrag af ledelsesberetningen i den seneste årsrapport.

G2B BioSolutions ApS — cvrprofil.dk